Compare · AXGN vs VAR
AXGN vs VAR
Side-by-side comparison of Axogen Inc. (AXGN) and Varian Medical Systems, Inc. (VAR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and VAR operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN carries a market cap of $2.09B.
- AXGN has hit the wire 6 times in the past 4 weeks while VAR has been quiet.
- AXGN has more recent analyst coverage (11 ratings vs 0 for VAR).
- Company
- Axogen Inc.
- Varian Medical Systems, Inc.
- Price
- -
- -
- Market cap
- $2.09B
- -
- 1M return
- -23.49%
- -
- 1Y return
- +108.70%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- n/a
- News (4w)
- 6
- 0
- Recent ratings
- 11
- 0
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Latest AXGN
- Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
- BofA Securities initiated coverage on AxoGen with a new price target
- Barclays initiated coverage on AxoGen with a new price target
- Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
- Axogen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
- SEC Form 424B5 filed by Axogen Inc.
- Amendment: Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
Latest VAR
- Icon Group First in World to Adopt New Multi-Disciplinary Oncology Information System from Varian
- Varian and Icon Group Partner to Extend Commitment to Global Cancer Care
- SEC Form 15-12B filed by Varian Medical Systems, Inc.
- SEC Form 4: Balser Jeffrey R. returned 2,824 units of Common Stock to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: BUTEL JEAN LUC returned 4,048 units of Common Stock to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: DUGAN REGINA E returned 12,396 units of Common Stock to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: ECKERT R ANDREW gifted 447 units of Common Stock and returned 13,826 units of Common Stock to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: BRUNER JUDY returned 6,779 units of Common Stock to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: ILLINGWORTH DAVID J returned 15,369 units of Common Stock to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: WILSON DOW R returned 39,231 units of Common Stock to the company and gifted 65,558 units of Common Stock, decreasing direct ownership by 100% to 0 units